Belgian biotechnology company at Leuven, founded in 2018 out of research at KU Leuven and the VIB, which develops selective inhibitors of histone deacetylase 6 that do not enter the brain's zinc binding sites in the usual way. Runs programmes in Charcot-Marie-Tooth disease and other peripheral neuropathies and in cardiac and metabolic disease, raised European venture funding to take its lead compound into clinical trials, and works with academic partners on translational studies.
No comments available.
Leave your rating & comment